Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL‐PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL‐PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecut...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Shrestha, Bikram, Sun, Yifei, Faisal, Farzana, Kim, Victoria, Soares, Kevin, Blair, Alex, Herman, Joseph M., Narang, Amol, Dholakia, Avani S., Rosati, Lauren, Hacker‐Prietz, Amy, Chen, Linda, Laheru, Daniel A., De Jesus‐Acosta, Ana, Le, Dung T., Donehower, Ross, Azad, Nilofar, Diaz, Luis A., Murphy, Adrian, Lee, Valerie, Fishman, Elliot K., Hruban, Ralph H., Liang, Tingbo, Cameron, John L., Makary, Martin, Weiss, Matthew J., Ahuja, Nita, He, Jin, Wolfgang, Christopher L., Huang, Chiung‐Yu, Zheng, Lei
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5504321/
https://ncbi.nlm.nih.gov/pubmed/28639410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1104
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares